Evidence map›Paper›PMID 31798449›Full record

ArticleFrontiers in pharmacology2019

CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice.

Fabio F Stellari, Angelo Sala, Francesca Ruscitti, Carola Buccellati, Andrew Allen, Patrizia Risé, Maurizio Civelli, Gino Villetti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Fabio F StellariPharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A, Parma, Italy.
Angelo SalaDepartment of Pharmaceutical Sciences, School of Drug Sciences, University of Milan, Milan, Italy.
Francesca RuscittiPharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A, Parma, Italy.
Carola BuccellatiDepartment of Pharmaceutical Sciences, School of Drug Sciences, University of Milan, Milan, Italy.
Andrew AllenPharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A, Parma, Italy.
Patrizia RiséDepartment of Pharmaceutical Sciences, School of Drug Sciences, University of Milan, Milan, Italy.
Maurizio CivelliPharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A, Parma, Italy.
Gino VillettiPharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A, Parma, Italy.
Chiesi (Italy) · ITUniversity of Milan · ITIstituto di Biomedicina e di Immunologia Molecolare Alberto Monroy · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibitors of phosphodiesterase 4 (PDE4) are potent anti-inflammatory agents, inhibiting the production of inflammatory mediators through the elevation of intracellular cAMP concentrations. We studied the activity of a novel PDE4 inhibitor, CHF6001, both

Indexed as

inhalation towersin vivo bioluminescence imagingLPSlung inflammationmouse modelNF-kBPDE4

Identifiers

PMID31798449
PMCPMC6863066
OpenAlexW2981505340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.